IFN a 2b Human, Yeast
(b) Analysis by SDS-PAGE.
Description
Interferon-alpha 2b Human Recombinant produced in yeast is a single, glycosylated, polypeptide chain containing 165 amino acids and having a molecular mass of approximately 19.3 kDa.
The IFN-a 2b is purified by proprietary chromatographic techniques.
Product Specs
Recombinant Human Interferon-alpha 2b, produced in yeast, is a single, glycosylated polypeptide chain with a molecular weight of approximately 19.3 kDa, comprising 165 amino acids. The purification process involves proprietary chromatographic techniques.
The product is lyophilized from a 0.2 μm filtered solution concentrated in PBS with a pH of 7.4 and containing 0.02% Tween-20.
The specific activity, as measured by an anti-viral assay, is at least 1.6 x 10⁸ IU/mg.
CDLPQTHSLG SRRTLMLLAQ MRRISLFSCL KDRHDFGFPQ EEFGNQFQKA ETIPVLHEMI QQIFNLFSTK DSSAAWDETL LDKFYTELYQ QLNDLEACVI QGVGVTETPL MKEDSILAVR KYFQRITLYL KEKKYSPCAW EVVRAEIMRS FSLSTNLQES LRSKE.
Product Science Overview
Interferons were first discovered in 1957 by Isaacs and Lindenmann, who identified their antiviral properties . The specific subtype, Interferon-Alpha 2b, was sequenced and produced recombinantly in E. coli in 1980 by Charles Weissmann’s laboratory at the University of Zurich . It was later developed by Biogen and marketed by Schering-Plough under the trade name Intron-A .
IFN-α2b exerts its effects by binding to specific receptors on the surface of target cells, initiating a cascade of intracellular events that lead to the expression of numerous interferon-stimulated genes (ISGs). These genes encode proteins that inhibit viral replication, enhance the immune response, and exert antiproliferative effects on tumor cells .
IFN-α2b has been approved for the treatment of various conditions, including:
- Chronic hepatitis B and C
- Hairy cell leukemia
- Chronic myelogenous leukemia
- Multiple myeloma
- Follicular lymphoma
- Malignant melanoma
It has also been investigated for its potential use in treating SARS-CoV-2 (COVID-19), showing promising results in reducing viral load and inflammatory cytokine levels .
One of the main challenges in the clinical use of IFN-α2b is its short half-life, which necessitates frequent dosing. Researchers are working on developing long-acting formulations to improve its therapeutic efficacy and patient compliance . Additionally, ongoing studies aim to better understand the molecular mechanisms underlying its diverse biological activities and to identify new therapeutic applications .
